Following the French healthcare system viewpoint, G-CSF + plerixafor was more costly (mean cost €10,958.00 versus €5097.00; p < 0.0001; 2012 values) and more effective (autologous SCT 86% versus 67%; p = 0.02) than high-dose cyclophosphamide in MM patients [63]. This evidence concerns the gene CSF3 and Miyoshi myopathy.